Literature DB >> 19477560

Quadrivalent meningococcal conjugate vaccines.

David Pace1, Andrew J Pollard, Nancy E Messonier.   

Abstract

Neisseria meningitidis is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. This vaccine and others in development offer the potential to broaden population protection against meningococcal disease.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19477560     DOI： 10.1016/j.vaccine.2009.05.003

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  23 in total

1.  Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody.

Authors:  Enrico Malito; Marco Biancucci; Agnese Faleri; Ilaria Ferlenghi; Maria Scarselli; Giulietta Maruggi; Paola Lo Surdo; Daniele Veggi; Alessia Liguori; Laura Santini; Isabella Bertoldi; Roberto Petracca; Sara Marchi; Giacomo Romagnoli; Elena Cartocci; Irene Vercellino; Silvana Savino; Glen Spraggon; Nathalie Norais; Mariagrazia Pizza; Rino Rappuoli; Vega Masignani; Matthew James Bottomley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

2.  Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

3.  Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP.

Authors:  Jay Lucidarme; Lynne S Newbold; Jamie Findlow; Stefanie Gilchrist; Stephen J Gray; Anthony D Carr; James Hewitt; Edward B Kaczmarski; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

Review 4.  Review of meningococcal group B vaccines.

Authors:  Dan M Granoff
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

5.  In silico analysis and modeling of ACP-MIP-PilQ chimeric antigen from Neisseria meningitidis serogroup B.

Authors:  Mehrdad Gholami; Alireza Salimi Chirani; Mona Moshiri; Mansour Sedighi; Abazar Pournajaf; Masoud Tohidfar; Gholamreza Irajian
Journal:  Rep Biochem Mol Biol       Date:  2015-10

6.  Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis.

Authors:  Raphael Simon; Sharon M Tennant; Jin Y Wang; Patrick J Schmidlein; Andrew Lees; Robert K Ernst; Marcela F Pasetti; James E Galen; Myron M Levine
Journal:  Infect Immun       Date:  2011-08-01       Impact factor: 3.441

7.  Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium.

Authors:  S Rondini; F Micoli; L Lanzilao; M Gavini; R Alfini; C Brandt; S Clare; P Mastroeni; A Saul; C A MacLennan
Journal:  Infect Immun       Date:  2014-12-29       Impact factor: 3.441

8.  Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989-2010).

Authors:  S Ben-Shimol; R Dagan; Y Schonmann; N Givon-Lavi; N Keller; C Block; I Kassis; M Ephros; D Greenberg
Journal:  Infection       Date:  2013-03-10       Impact factor: 3.553

9.  Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines.

Authors:  Mary Adetinuke Boyd; Sharon M Tennant; Venant A Saague; Raphael Simon; Khitam Muhsen; Girish Ramachandran; Alan S Cross; James E Galen; Marcela F Pasetti; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2014-03-12

10.  Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.

Authors:  Timo Vesikari; Aino Forstén; Dominique Boutriau; Véronique Bianco; Marie Van der Wielen; Jacqueline M Miller
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.